metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mUC - L1 - all population metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - all population
versus gemcitabine plus platin
	durvalumab alone
	DANUBE (D vs C - all population), 2020 Urologe A 2016; 55:1097-8 Lancet Oncol 2020 Sep 21;S1470-2045(20)30541-6. NCT02516241	RCT	mUC - L1 - all population	durvalumab	platine based chemotherpy (SOC) cisplatine plus gemcitabine	first line in Patients with Stage IV Urothelial Cancer.	346 / 344	some concern	inconclusive	statistically significant 64 % decrease in objective responses (ORR)
mUC - L1 - PDL1 positive metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - PDL1 positive
versus gemcitabine plus platin
	durvalumab alone
	DANUBE (D vs C - PDL1>25%), 2020 Urologe A 2016; 55:1097-8 Lancet Oncol 2020 Sep 21;S1470-2045(20)30541-6. NCT02516241	RCT	mUC - L1 - PDL1 positive	durvalumab	platine based chemotherapy (gemcitabine)	first line in Patients with Stage IV Urothelial Cancer whose tumours express high levels of PD-L1.	209 / 207	some concern	inconclusive	inconclusive 11 % decrease in deaths (OS) (PE) statistically significant 59 % decrease in objective responses (ORR)